<p>北京 --（商业资讯）-- 科兴生物科技有限公司（NASDAQ: SVA）（“ <strong>科兴</strong>” 或 “ <strong>公司</strong>”），中国领先的生物制药产品供应商，今天宣布收到纳斯达克上市资格（“ <strong>纳斯达克</strong>”）于 2026 年 1 月 2 日发出的通知函（“ <strong>通知函</strong>”），指出由于公司未能及时提交包含 2025 年第二季度末的临时资产负债表和损益表的 6-K 表格，公司未符合纳斯达克上市规则 5250(c)(2) 的要求。</p>
<p>如之前披露的，公司于 2025 年 11 月收到纳斯达克发出的退市决定函（“ <strong>工作人员决定</strong>”）。公司于 2025 年 11 月 19 日请求纳斯达克听证委员会举行听证会，以对工作人员决定提出上诉。纳斯达克已通知公司，纳斯达克听证委员会将在 2026 年 1 月 8 日的听证会上考虑通知函中提到的事项，公司已被邀请就此事表达其观点。</p>
<p>公司正在评估通知函，并打算在计划的听证会上向纳斯达克听证委员会提出其计划和观点，目标是维持其纳斯达克上市资格。</p>
<p><strong>安全港声明</strong></p>
<p>本公告包含根据 1934 年证券交易法第 21E 条及 1995 年美国私人证券诉讼改革法的定义的前瞻性陈述。这些前瞻性陈述可以通过诸如 “可能”、“将”、“期望”、“预期”、“旨在”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能会” 等类似表达来识别。这些陈述基于当前的预期和市场及运营条件，并涉及已知或未知的风险、不确定性和其他因素，所有这些因素都难以预测，并且许多因素超出了公司或董事会的控制，可能导致实际结果、表现或成就与前瞻性陈述中的内容有重大差异。有关这些及其他风险、不确定性或因素的进一步信息已包含在公司向美国证券交易委员会提交的文件中。公司及董事会不承担因新信息、未来事件或其他原因而更新任何前瞻性陈述的义务，除非法律要求。</p>
<p><strong>关于科兴</strong></p>
<p>科兴生物科技有限公司（科兴）是一家总部位于中国的全球生物制药公司，使命是 “提供疫苗以消除人类疾病”，公司专注于疫苗及相关生物产品的研究、开发、生产和商业化，这些产品可保护人类免受传染病的侵害。</p>
<p>公司的多元化产品组合包括流感、病毒性肝炎、水痘、手足口病（HFMD）、小儿麻痹症、肺炎球菌疾病等疫苗，其中有 3 种疫苗已获得世界卫生组织的预认证，包括灭活乙型肝炎疫苗 Healive®、Sabin 株灭活脊髓灰质炎疫苗（sIPV）和水痘疫苗。</p>
<p>科兴在开发应对传染病疫情的疫苗方面处于领先地位，并且在重大公共卫生紧急事件期间率先开展研发，包括 SARS、H5N1、H1N1 和 COVID-19。公司开发了全球首个灭活 SARS 疫苗（第一阶段已完成）、中国首个 H5N1 流感疫苗（Panflu®）、全球首个 H1N1 流感疫苗（Panflu.1®）和 CoronaVac®，这是全球使用最广泛的灭活 COVID-19 疫苗。</p>
<p>除了已上市的产品组合外，公司还在推进一个强大的研发管道，包括组合疫苗、重组蛋白疫苗和下一代平台，如 mRNA 技术和抗体。</p>
<p>科兴长期致力于创新和全球健康，通过加强与研究机构、国际组织和地方合作伙伴的合作，扩大其全球足迹。通过更广泛的市场存在、技术合作和本地化生产，公司旨在加速疫苗的开发和供应，提高高质量产品的区域可及性，更好地满足未满足的医疗需求，同时提高对未来疫情的应对能力。</p>
<p>欲了解更多信息，请访问公司网站 www.sinovac.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDQ2MDA1OTNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDQ2MDA1OTNyMQ"/></p>
<p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20260104600593/en/</p>
<p>投资者和媒体联系</p>
<p>科兴生物科技有限公司</p>
<p>电子邮件：ir@sinovac.com</p>
<p>来源：科兴生物科技有限公司</p>

<p>赛诺菲生物科技有限公司（NASDAQ: SVA）已收到纳斯达克关于未遵守上市规则 5250(c)(2) 的通知，原因是其 2025 年半年度报告提交延迟。该公司此前于 2025 年 11 月收到了退市决定，并已请求举行听证会以对该决定提出上诉。听证会定于 2026 年 1 月 8 日举行，赛诺菲将提交其案例以维持其纳斯达克上市资格</p>

<p>BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“ <strong>SINOVAC</strong>” or the “ <strong>Company</strong>”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “ <strong>Notification Letter</strong>”) from Nasdaq Listing Qualifications (“ <strong>Nasdaq</strong>”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025.</p>
<div class="lb-trans"><p>北京 --（商业资讯）-- 科兴生物科技有限公司（NASDAQ: SVA）（“ <strong>科兴</strong>” 或 “ <strong>公司</strong>”），中国领先的生物制药产品供应商，今天宣布收到纳斯达克上市资格（“ <strong>纳斯达克</strong>”）于 2026 年 1 月 2 日发出的通知函（“ <strong>通知函</strong>”），指出由于公司未能及时提交包含 2025 年第二季度末的临时资产负债表和损益表的 6-K 表格，公司未符合纳斯达克上市规则 5250(c)(2) 的要求。</p>
</div><p>As previously disclosed, the Company received a delisting determination letter (the “ <strong>Staff Determination</strong>”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present its views regarding this matter.</p>
<div class="lb-trans"><p>如之前披露的，公司于 2025 年 11 月收到纳斯达克发出的退市决定函（“ <strong>工作人员决定</strong>”）。公司于 2025 年 11 月 19 日请求纳斯达克听证委员会举行听证会，以对工作人员决定提出上诉。纳斯达克已通知公司，纳斯达克听证委员会将在 2026 年 1 月 8 日的听证会上考虑通知函中提到的事项，公司已被邀请就此事表达其观点。</p>
</div><p>The Company is evaluating the Notification Letter and intends to present its plan and views to the Nasdaq Hearings Panel at the scheduled hearing with the objective of maintaining its Nasdaq listing.</p>
<div class="lb-trans"><p>公司正在评估通知函，并打算在计划的听证会上向纳斯达克听证委员会提出其计划和观点，目标是维持其纳斯达克上市资格。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;aim,&#34; &#34;estimate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;is/are likely to&#34; or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.</p>
<div class="lb-trans"><p>本公告包含根据 1934 年证券交易法第 21E 条及 1995 年美国私人证券诉讼改革法的定义的前瞻性陈述。这些前瞻性陈述可以通过诸如 “可能”、“将”、“期望”、“预期”、“旨在”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能会” 等类似表达来识别。这些陈述基于当前的预期和市场及运营条件，并涉及已知或未知的风险、不确定性和其他因素，所有这些因素都难以预测，并且许多因素超出了公司或董事会的控制，可能导致实际结果、表现或成就与前瞻性陈述中的内容有重大差异。有关这些及其他风险、不确定性或因素的进一步信息已包含在公司向美国证券交易委员会提交的文件中。公司及董事会不承担因新信息、未来事件或其他原因而更新任何前瞻性陈述的义务，除非法律要求。</p>
</div><p><strong>About SINOVAC</strong></p>
<div class="lb-trans"><p><strong>关于科兴</strong></p>
</div><p>Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of &#34;supply vaccines to eliminate human diseases&#34;, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.</p>
<div class="lb-trans"><p>科兴生物科技有限公司（科兴）是一家总部位于中国的全球生物制药公司，使命是 “提供疫苗以消除人类疾病”，公司专注于疫苗及相关生物产品的研究、开发、生产和商业化，这些产品可保护人类免受传染病的侵害。</p>
</div><p>The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.</p>
<div class="lb-trans"><p>公司的多元化产品组合包括流感、病毒性肝炎、水痘、手足口病（HFMD）、小儿麻痹症、肺炎球菌疾病等疫苗，其中有 3 种疫苗已获得世界卫生组织的预认证，包括灭活乙型肝炎疫苗 Healive®、Sabin 株灭活脊髓灰质炎疫苗（sIPV）和水痘疫苗。</p>
</div><p>SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&amp;D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.</p>
<div class="lb-trans"><p>科兴在开发应对传染病疫情的疫苗方面处于领先地位，并且在重大公共卫生紧急事件期间率先开展研发，包括 SARS、H5N1、H1N1 和 COVID-19。公司开发了全球首个灭活 SARS 疫苗（第一阶段已完成）、中国首个 H5N1 流感疫苗（Panflu®）、全球首个 H1N1 流感疫苗（Panflu.1®）和 CoronaVac®，这是全球使用最广泛的灭活 COVID-19 疫苗。</p>
</div><p>Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.</p>
<div class="lb-trans"><p>除了已上市的产品组合外，公司还在推进一个强大的研发管道，包括组合疫苗、重组蛋白疫苗和下一代平台，如 mRNA 技术和抗体。</p>
</div><p>With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.</p>
<div class="lb-trans"><p>科兴长期致力于创新和全球健康，通过加强与研究机构、国际组织和地方合作伙伴的合作，扩大其全球足迹。通过更广泛的市场存在、技术合作和本地化生产，公司旨在加速疫苗的开发和供应，提高高质量产品的区域可及性，更好地满足未满足的医疗需求，同时提高对未来疫情的应对能力。</p>
</div><p>For more information, please see the Company’s website at www.sinovac.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问公司网站 www.sinovac.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDQ2MDA1OTNyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260104600593r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260104600593/en/</p>
<div class="lb-trans"><p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20260104600593/en/</p>
</div><p>Investor and Media Contact</p>
<div class="lb-trans"><p>投资者和媒体联系</p>
</div><p>Sinovac Biotech Ltd.</p>
<div class="lb-trans"><p>科兴生物科技有限公司</p>
</div><p>Email: ir@sinovac.com</p>
<div class="lb-trans"><p>电子邮件：ir@sinovac.com</p>
</div><p>Source: Sinovac Biotech Ltd.</p>
<div class="lb-trans"><p>来源：科兴生物科技有限公司</p>
</div>

科兴生物收到纳斯达克关于 2025 年半年报迟交的通知 | SVA 股票资讯